BR0016463A - Compostos de n-(1-feniletil)-5-fenil-imidazol-2-amina, suas composições e usos - Google Patents

Compostos de n-(1-feniletil)-5-fenil-imidazol-2-amina, suas composições e usos

Info

Publication number
BR0016463A
BR0016463A BR0016463-1A BR0016463A BR0016463A BR 0016463 A BR0016463 A BR 0016463A BR 0016463 A BR0016463 A BR 0016463A BR 0016463 A BR0016463 A BR 0016463A
Authority
BR
Brazil
Prior art keywords
phenyl
compounds
compositions
amine compounds
phenylethyl
Prior art date
Application number
BR0016463-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Song Liu
Benjamin Eric Blass
David Edward Portlock
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR0016463A publication Critical patent/BR0016463A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
BR0016463-1A 1999-12-17 2000-12-14 Compostos de n-(1-feniletil)-5-fenil-imidazol-2-amina, suas composições e usos BR0016463A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17270999P 1999-12-17 1999-12-17
US19281100P 2000-03-29 2000-03-29
PCT/US2000/033820 WO2001044203A1 (en) 1999-12-17 2000-12-14 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses

Publications (1)

Publication Number Publication Date
BR0016463A true BR0016463A (pt) 2002-08-27

Family

ID=26868376

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016463-1A BR0016463A (pt) 1999-12-17 2000-12-14 Compostos de n-(1-feniletil)-5-fenil-imidazol-2-amina, suas composições e usos

Country Status (16)

Country Link
EP (1) EP1237876A1 (xx)
JP (1) JP2003516972A (xx)
KR (1) KR20020062339A (xx)
CN (1) CN1411449A (xx)
AU (1) AU2096901A (xx)
BR (1) BR0016463A (xx)
CA (1) CA2394570A1 (xx)
CO (1) CO5261516A1 (xx)
CZ (1) CZ20021834A3 (xx)
HU (1) HUP0204144A3 (xx)
IL (1) IL149749A0 (xx)
MX (1) MXPA02005957A (xx)
NO (1) NO20022844L (xx)
PE (1) PE20010928A1 (xx)
PL (1) PL356172A1 (xx)
WO (1) WO2001044203A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2367661C2 (ru) 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459763A (en) * 1966-01-25 1969-08-05 Geigy Chem Corp Certain amino imidazole derivatives
JPS54112864A (en) * 1978-02-22 1979-09-04 Teijin Ltd Novel imidazole derivative, its mineral acid salt, and their preparation
DD135724A1 (de) * 1978-04-14 1979-05-23 Annemarie Hetzheim Verfahren zur herstellung von 2-amino-3-phenacyl-benzoxazoliumhalogeniden und 2-amino-1-o-hydroxyphenyl-4-aryl-imidazolen
US4348404A (en) * 1980-07-21 1982-09-07 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
JPH0753716B2 (ja) * 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
MXPA01011860A (es) * 1999-05-19 2002-05-06 Procter & Gamble Compuestos heterociclicos que contienen imidazo, sus composiciones y usos.

Also Published As

Publication number Publication date
PE20010928A1 (es) 2001-09-12
WO2001044203A1 (en) 2001-06-21
CO5261516A1 (es) 2003-03-31
KR20020062339A (ko) 2002-07-25
CN1411449A (zh) 2003-04-16
CZ20021834A3 (cs) 2002-10-16
JP2003516972A (ja) 2003-05-20
MXPA02005957A (es) 2002-10-23
HUP0204144A3 (en) 2003-07-28
NO20022844D0 (no) 2002-06-14
IL149749A0 (en) 2002-11-10
HUP0204144A2 (en) 2003-05-28
NO20022844L (no) 2002-08-19
AU2096901A (en) 2001-06-25
PL356172A1 (en) 2004-06-14
EP1237876A1 (en) 2002-09-11
CA2394570A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
ES2193391T3 (es) Antagonistas muscarinicos.
PA8481301A1 (es) Derivados de 4,4-biarilpiperidina
BR9806413A (pt) Composto e uso do mesmo
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
BR9807876A (pt) Compostos heterocìclicos e seu uso para inibição de peptìdeo beta-amilóide
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
SE9504661D0 (sv) New compounds
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
BR0312232A (pt) Inibidores de caspases e seus usos
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DE60045508D1 (de) Dalda-analoge und ihre verwendung
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
CO4410330A1 (es) Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida
BR0008321A (pt) Secretagogos de hormÈnio de crescimento
UY26426A1 (es) Nuevos compuestos
DK0527081T3 (da) Hidtil ukendte substituerede 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-oner, deres fremstilling og terapeutiske anvendelse
NO20014240L (no) C16-umettede FP-selektive prostaglandinanaloger
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]